Chemed (CHE) and Its Rivals Head-To-Head Comparison

Chemed (NYSE:CHEGet Free Report) is one of 235 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare Chemed to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Chemed and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemed 0 5 1 0 2.17
Chemed Competitors 1792 7547 12968 789 2.55

Chemed presently has a consensus target price of $530.75, indicating a potential upside of 1.91%. As a group, “Healthcare Providers & Services” companies have a potential upside of 14.51%. Given Chemed’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Chemed has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Chemed and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Chemed $2.53 billion $265.24 million 26.16
Chemed Competitors $20.60 billion $281.57 million 1.50

Chemed’s rivals have higher revenue and earnings than Chemed. Chemed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Dividends

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. Chemed pays out 14.1% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.5% and pay out 25.4% of their earnings in the form of a dividend. Chemed has raised its dividend for 16 consecutive years.

Insider & Institutional Ownership

95.8% of Chemed shares are owned by institutional investors. Comparatively, 56.9% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 15.4% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Chemed’s rivals have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Chemed and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chemed 10.60% 31.77% 18.90%
Chemed Competitors -7.69% -139.74% -1.50%

Summary

Chemed rivals beat Chemed on 9 of the 15 factors compared.

About Chemed

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.